Last updated on July 2019

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive HER2-Negative Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma


Brief description of study

The purpose of this study is to evaluate the efficacy of zolbetuximab plus capecitabine and oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) as measured by Progression Free Survival (PFS).

This study will also evaluate efficacy, safety and tolerability of zolbetuximab, as well as its effects on quality of life. Pharmacokinetics (PK) of zolbetuximab and the immunogenicity profile of zolbetuximab will be evaluated as well.

Detailed Study Description

The study consists of the following periods: screening; treatment; post-treatment follow up, safety follow up, long term and survival follow-up.

Clinical Study Identifier: NCT03653507

Find a site near you

Start Over

Pacific Cancer Care

Monterey, CA United States
  Connect »

New Mexico Oncology Hematology

Albuquerque, NM United States
  Connect »

Site HR38501

Varazdin, Croatia
  Connect »

Site GR30004

Heraklion, Greece
  Connect »

Site GR30003

Larissa, Greece
  Connect »

Site GR30005

Neo Faliro, Piraeus, Greece
  Connect »

Site GR30002

Thessaloniki, Greece
  Connect »

Site GR30006

Thessaloniki, Greece
  Connect »

Site JP81004

Kita-gun, Japan
  Connect »

Site JP81003

Kawasaki, Japan
  Connect »

Site JP81001

Yokohama, Japan
  Connect »

Site JP81005

Utsunomiya, Japan
  Connect »

Site KR82002

Daegu, Korea, Republic of
  Connect »

Site KR82006

Goyang-si, Korea, Republic of
  Connect »

Site KR82007

Gyeonggi-do, Korea, Republic of
  Connect »

Site KR82008

Hwasungun, Korea, Republic of
  Connect »

Site KR82010

Jeonju-si, Korea, Republic of
  Connect »

Site KR82001

Seoul, Korea, Republic of
  Connect »

Site KR82003

Seoul, Korea, Republic of
  Connect »

Site KR82009

Suwon, Korea, Republic of
  Connect »

Site MY60001

Georgetown, Malaysia
  Connect »

Site MY60004

Kota Kinabalu, Malaysia
  Connect »

Site MY60002

Kuala Lumpur, Malaysia
  Connect »

Site MY60003

Kuala Lumpur, Malaysia
  Connect »

Site MY60005

Kuala Lumpur, Malaysia
  Connect »

Site ES34006

Barcelona, Spain
  Connect »

Site ES34009

Barcelona, Spain
  Connect »

Site ES34010

Barcelona, Spain
  Connect »

Site ES34004

Pamplona, Spain
  Connect »

Site ES34007

Valencia, Spain
  Connect »

Site ES34012

Valencia, Spain
  Connect »

Site TW88602

Kaohsiung, Taiwan
  Connect »

Site TW88603

Taichung, Taiwan
  Connect »

Site TH66002

Bangkok, Thailand
  Connect »

Site TH66001

Muang, Thailand
  Connect »

Site TH66003

Muang, Thailand
  Connect »

Site TH66004

Songkla, Thailand
  Connect »

Site TR90004

Balcali, Turkey
  Connect »

Site TR90012

Bornova, Turkey
  Connect »

Site TR90010

Istanbul, Turkey
  Connect »

Site TR90013

Konyaalti, Turkey
  Connect »

Site TR90011

Malatya, Turkey
  Connect »

Site CA15004

Calgary, Canada
  Connect »

Site IE35301

Dublin, Ireland
  Connect »

Site PT35104

Santa Maria da Feira, Portugal
  Connect »

Mercy Clinic Oncology and Hematology

Oklahoma City, OK United States
  Connect »

Site PT35108

Porto, Portugal
  Connect »

Site TH66005

Bangkok, Thailand
  Connect »

Site TR90002

Istanbul, Turkey
  Connect »

Site HR38504

Osijek, Croatia
  Connect »

Site PT35109

Braga, Portugal
  Connect »

Site PT35110

Coimbra, Portugal
  Connect »

Site PT35101

Setubal, Portugal
  Connect »

Site HR38503

Zagreb, Croatia
  Connect »

Site CA15002

Rimouski, QC Canada
  Connect »

Site PT35107

Vila Real, Portugal
  Connect »

Site PT35106

Lisboa, Portugal
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.